Vimarsana
Biggest News Aggregation in the World

Page 6 - Ctla 4 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ctla 4. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ctla 4 Today - Breaking & Trending Today

Study explores the effect of age-associated B cells on COVID-19 vaccine-induced immunity - Vimarsana News

Study explores the effect of age-associated B cells on COVID-19 vaccine-induced immunity

In a new study, a team of researchers explored the effect of immune checkpoint blockade (ICB)-induced expansion of age-associated B cells (ABCs) on COVID-19 vaccine-derived humoral immunity in patients with cancer and inborn errors of immunity (IEI).

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale - Vimarsana News

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy - Vimarsana News

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease - Vimarsana News

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma - Vimarsana News

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug – a CTLA-4 inhibitor such as the drug ipilimumab.